Claims
- 1. A composition comprising at least one 1-nitroacridine derivative and at least one antiangiogenic substance.
- 2. The composition according to claim 1, wherein said 1-nitroacridine derivative is a 1-nitro-9-alkylaminoacridine derivative.
- 3. The composition according to claim 1, wherein said 1-nitroacridine derivative is a 1-nitro-9-hydroxyalkylaminoacridine or 1-nitro-9-alkoxyalkylaminoacridine.
- 4. The composition according to claim 1, wherein the antiangiogenic substance is selected from the group consisting of angiostatin, endostatin, pancratistatin, phenstatin and combretastatin.
- 5. A composition comprising at least one 1-nitroacridine derivative and at least one substance that inhibits tumor vasculature or biochemical processes that affect new blood vessel growth.
- 6. A method for preventing or inhibiting tumor growth in a mammal comprising administering to said animal an amount of at least one 1-nitroacridine derivative and at least one antiangiogenic substance effective to inhibit or prevent tumor growth.
- 7. A method for preventing or inhibiting metastases in a mammal comprising administering to said animal an amount of at least one 1-nitroacridine derivative and at least one antiangiogenic substance effective to prevent or inhibit metastases.
- 8. The method according to claim 6 in which the tumor is selected from the group consisting of breast cancer, prostate cancer, colon cancer, lymphoma, sarcoma, and leukemia.
- 9. The method according to claim 6, wherein the tumor is a prostate tumor.
- 10. A method for inhibiting or preventing tumor growth in a mammal comprising administering to said animal an amount of the composition of claim 1 effective to inhibit or prevent tumor growth.
- 11. A method for preventing or inhibiting metastases in a mammal comprising administering to said animal an amount of the composition of claim 1 effective to prevent or inhibit metastases
- 12. A composition comprising (a) at least one 1-nitroacridine derivative selected from the group consisting of a 1-nitro-9-hydroxyalkylaminoacridine and 1-nitro-9-alkoxyalkylaminoacridine derivative and (b) at least one tumor inhibitor substance.
- 13. The composition of claim 12, wherein the tumor inhibitor substance is selected from the group consisting of an antiangiogenic substance, a cytokine, a growth factor inhibitor, a steroid, a hormone inhibitor, a small peptide that modulates cell growth or induces apoptosis, a nucleic acid synthesis inhibitor, a cytotoxic agent, a cytostatic agent, an antimitotic agent and a cell cycle inhibitor.
- 14. A composition comprising (a) at least one 1-nitroacridine derivative selected from the group consisting of a 1-nitro-9-hydroxyalkylaminoacridine and 1-nitro-9-alkoxyalkylaminoacridine and (b) at least one antiangiogenic substance.
- 15. The composition according to claim 13, wherein the 1-nitroacridine derivative is selected from the group consisting of 1-nitro-9-hydroxyethylaminoacridine, 9-(2′-hydroxyethylamino)-4-methyl-1-nitroacridine, 9-(2′-hydroxyethylamino)-7-methoxy-1-nitroacridine, 9-(2′-hydroxyethylamino)-7-methoxy-4-methyl-1-nitroacridine, 9-(2′-acetoxyethylamino)-1-nitroacridine, 9-(2′-propionoxyethylamino)-1-nitroacridine, 9-(3′-hydroxypropylamino)-7-methoxy-1-nitroacridine, 9-(3′-hydroxypropylamino)-4-methyl-1-nitroacridine, 9-(2′-acetoxyethylamino)-4-methyl-1-nitroacridine, 9-(2′-propionoxyethylamino)-4-methyl-1-nitroacridine, 9-(3′-acetoxypropylamino)-4-methyl-1-nitroacridine, 9-(2′-propionoxypropylamino)-4-methyl-1-nitroacridine, 9-(2′-hydroxyethylamino)-4-methoxy-1-nitroacridine, 9-(3′-hydroxypropylamino)-4-methoxy-1-nitroacridine, 9-(4′-hydroxybutylamino)-4-methoxy-1-nitroacridine, 9-(4′-hydroxybutylamino)-7-methoxy-1-nitroacridine and 9-(2′-acetoxyethylamino)-7-methoxy-4-methyl-1-nitroacridine.
- 16. The composition according to claim 13, wherein the antiangiogenic substance is selected from the group consisting of angiostatin, endostatin, pancratistatin, phenstatin, fumagillin, TNP-470 and combretastatin.
- 17. A method for inhibiting or preventing tumor growth in a mammal comprising administering to said animal an amount of at least one 1-nitroacridine derivative selected from the group consisting of a 1-nitro-9-hydroxyalkylaminoacridine, 1-nitro-9-alkoxyalkylaminoacridine and 1-nitro-9-alkylcarboxyalkylaminoacridine derivative and an amount of at least one tumor inhibitor substance effective to inhibit or prevent tumor growth.
- 18. A method for preventing or inhibiting metastases in a mammal comprising administering to said animal an amount of at least one 1-nitroacridine derivative selected from the group consisting of a 1-nitro-9-hydroxyalkylaminoacridine, 1-nitro-9-alkoxyalkylaminoacridine and 1-nitro-9-alkylcarboxyalkylaminoacridine derivative and an amount of at least one tumor inhibitor substance effective to prevent or inhibit metastases.
- 19. A method for inhibiting or preventing prostate tumor growth in a mammal comprising administering to said animal a 1-nitroacridine derivative and a tumor inhibitor substance in an amount effective to inhibit or prevent said prostate tumor growth.
- 20. The method according to claim 18, in which the mammal is a human patient.
PRIORITY CLAIM
[0001] This application claims priority from provisional application serial No. 60/183,529, filed Feb. 18, 2000, under 35 U.S.C. §119 (e), the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60183529 |
Feb 2000 |
US |